<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39402600</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6963</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMC health services research</Title><ISOAbbreviation>BMC Health Serv Res</ISOAbbreviation></Journal><ArticleTitle>Cost of COVID-19 vaccine delivery in nine States in Nigeria via the U.S. Government Initiative for Global Vaccine Access.</ArticleTitle><Pagination><StartPage>1232</StartPage><MedlinePgn>1232</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1232</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12913-024-11645-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In 2022, the U.S. Centers for Disease Control and Prevention collaborated with implementing partners, African Field Epidemiology Network and Sydani Group, to support COVID-19 vaccination efforts in Nigeria. To characterize the costs of COVID-19 vaccination, this study evaluated financial costs per dose for activities implemented to support the intensification campaign for COVID-19 vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This retrospective evaluation collected secondary data from existing expenditure and programmatic records on resource utilization to roll out COVID-19 vaccination during 2022. The study included incremental financial costs of the activities implemented to support an intensification campaign for COVID-19 vaccination across nine states and six administrative levels in Nigeria from the perspective of the external donor (U.S. Government). Costs for vaccines and injection supplies, transport of vaccines, and any economic costs, including government in-kind contributions, were not included. All costs were converted from Nigerian Naira to 2022 U.S. Dollars (US$).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The estimated financial delivery cost of the COVID-19 vaccination intensification campaign was US$0.84 per dose (total expenditure of US$6.29 million to administer 7,461,971 doses). Most of the financial resources were used for fieldwork activities (86%), followed by monitoring and supervision activities (8%), coordination activities (5%), and training-related activities (1%). Labor (58%) and travel (37%) were the resource inputs that accounted for the majority of the cost, while shares of other resource inputs were marginal (1% for each). Most labor costs (79%) were spent on payments for mass vaccination campaign teams, including pay-for-performance incentives. By administrative level, the largest share of costs (46%) was for pay-for-performance incentives at the community, health facility, or campus levels combined, followed by local government area level (24%), community level only (15%), state level (9%), national level (3%), campus level only (1%), and health facility level only (&lt; 1%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Findings from the evaluation can help to inform resources needed for vaccination activities to respond to future outbreaks and pandemics in resource-limited settings, particularly to reach new target populations not regularly included in routine childhood immunization delivery.</AbstractText><CopyrightInformation>© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noh</LastName><ForeName>Dave Haeyun</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, USA. hnoh@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Darwar</LastName><ForeName>Roopa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uba</LastName><ForeName>Belinda V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gab-Deedam</LastName><ForeName>Shiva</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sydani Group Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yani</LastName><ForeName>Stella</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimoh</LastName><ForeName>Akolade</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sydani Group Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waziri</LastName><ForeName>Ndadilnasiya</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>David</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sydani Group Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amoo</LastName><ForeName>Babatunde</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atobatele</LastName><ForeName>Sunday</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sydani Group Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydani Institute for Research and Innovation (SIRI), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimas</LastName><ForeName>Janada</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fadahunsi</LastName><ForeName>Rhoda</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampson</LastName><ForeName>Sidney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sydani Group Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sydani Institute for Research and Innovation (SIRI), Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simple</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ugbenyo</LastName><ForeName>Gideon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wisdom</LastName><ForeName>Margeret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network (AFENET) Nigeria, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asekun</LastName><ForeName>Adeyelu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallas</LastName><ForeName>Sarah W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikwe</LastName><ForeName>Hadley</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Global Immunization Division, Global Health Center, Centers for Disease Control and Prevention, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Health Serv Res</MedlineTA><NlmUniqueID>101088677</NlmUniqueID><ISSNLinking>1472-6963</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000600" MajorTopicYN="N">supply &amp; distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006297" MajorTopicYN="N">Health Services Accessibility</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Costs</Keyword><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>23</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39402600</ArticleId><ArticleId IdType="pmc">PMC11472445</ArticleId><ArticleId IdType="doi">10.1186/s12913-024-11645-1</ArticleId><ArticleId IdType="pii">10.1186/s12913-024-11645-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haldane V, De Foo C, Abdalla SM, Jung A-S, Tan M, Wu S, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med. 2021;27:964–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397:1023–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906643</ArticleId><ArticleId IdType="pubmed">33587887</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Agency for International Development. Global VAX: a new ‘Initiative for Global Vaccine Access’ to accelerate U.S. vaccine delivery assistance around the world. 2022. Available from: https://www.usaid.gov/coronavirus/fact-sheets/global-vax. Cited 23 Jan 2024.</Citation></Reference><Reference><Citation>U.S. Agency for International Development. The U.S. Government Initiative for Global Vaccine Access: vaccinating the world against COVID-19. 2023. Available from: https://www.usaid.gov/sites/default/files/2023-09/USAID_COVID_GVAX_Capstone_Report-082423_final_508.pdf. Cited 8 Feb 2024.</Citation></Reference><Reference><Citation>U.S. Embassy and Consulate in Nigeria. U.S. Government’s Initiative for Global Vaccine Access to boost COVID-19 vaccination in Nigeria. 2022. Available from: https://ng.usembassy.gov/u-s-governments-initiative-for-global-vaccine-access-initiative-to-boost-covid-19-vaccination-in-nigeria/. Cited 23 Jan 2024.</Citation></Reference><Reference><Citation>Rosenthal MB, Fernandopulle R, Song HR, Landon B. Paying for quality: providers’ incentives for quality improvement. Health Aff. 2004;23:127–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15046137</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal MB, Frank RG, Li Z, Epstein AM. Early experience with pay-for-performance: from concept to practice. JAMA. 2005;294:1788–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16219882</ArticleId></ArticleIdList></Reference><Reference><Citation>Roski J, Jeddeloh R, An L, Lando H, Hannan P, Hall C, et al. The impact of financial incentives and a patient registry on preventive care quality: increasing provider adherence to evidence-based smoking cessation practice guidelines. Prev Med. 2003;36:291–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634020</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco LM, Bennett S, Kanfer R. Health sector reform and public sector health worker motivation: a conceptual framework. Soc Sci Med. 2002;54:1255–66.</Citation><ArticleIdList><ArticleId IdType="pubmed">11989961</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A, Deaton A, Duflo E. Health, health care, and economic development: wealth, health, and health services in rural Rajasthan. Am Econ Review. 2004;94:326–30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2658609</ArticleId><ArticleId IdType="pubmed">19305517</ArticleId></ArticleIdList></Reference><Reference><Citation>Das J, Hammer J, Leonard K. The quality of medical advice in low-income countries. J Econ Perspect. 2008;22:93–114.</Citation><ArticleIdList><ArticleId IdType="pubmed">19768841</ArticleId></ArticleIdList></Reference><Reference><Citation>Das J, Hammer J. Money for nothing: the dire straits of medical practice in Delhi. India J Dev Econ. 2007;83:1–36.</Citation></Reference><Reference><Citation>Mohanan M, Vera-Hernández M, Das V, Giardili S, Goldhaber-Fiebert JD, Rabin TL, et al. The know-do gap in quality of health care for childhood diarrhea and pneumonia in rural India. JAMA Pediatr. 2015;169:349–57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5023324</ArticleId><ArticleId IdType="pubmed">25686357</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis M, Pettersson Gelander G. Governance in health care delivery: raising performance. World Bank Policy Research Working Paper 5074. 2009.</Citation></Reference><Reference><Citation>Vaughan K, Griffiths UK, Rankgoane-Pono G, Mokena OT, Modise M, Moalosi M, et al. Estimation of COVID-19 vaccine delivery costs in Botswana. 2023. UNICEF &amp; Botswana Ministry of Health. Available from: https://immunizationeconomics.org/wp-content/uploads/2023/09/EstimationofCOVID-19vaccinedelive.pdf. Cited 25 Jan 2024.</Citation></Reference><Reference><Citation>Vaughan K, Smith E, Schütte C, Moi F, Boonstoppel L. The cost of delivering COVID-19 vaccines in Côte d’Ivoire. 2023. ThinkWell &amp; Genesis Analytics. Available from: https://thinkwell.global/wp-content/uploads/2023/09/Cote-dIvoire-final-report_FINAL.pdf. Cited 25 Jan 2024.</Citation></Reference><Reference><Citation>Namalela T, Moi F, Dipuve A, Boonstoppel L. The cost of delivering COVID-19 vaccines in Mozambique. 2023. ThinkWell. Available from: https://thinkwell.global/wp-content/uploads/2023/12/Cost-of-delivering-C19-vax-in-Moz_final.pdf. Cited 25 Jan 2024.</Citation></Reference><Reference><Citation>Immunization Economics Community of Practice. COVID-19 vaccine delivery costing. 2023. Available from: https://immunizationeconomics.org/covid19-vaccine-delivery-costing. Cited 24 Jan 2024.</Citation></Reference><Reference><Citation>Moi, F., Boonstoppel, L., Archer, R., Akilimali, P. The Cost of Delivering COVID-19 Vaccines in the Democratic Republic of the Congo. 2024. ThinkWell. Available from: https://thinkwell.global/wp-content/uploads/2024/04/DRC-C19-costing-study-report_final.pdf. Cited 2 Aug 2024.</Citation></Reference><Reference><Citation>Orangi S, Ojal J, Brand SP, Orlendo C, Kairu A, Aziza R, et al. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya. BMJ Glob Health. 2022;7:e009430.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9344598</ArticleId><ArticleId IdType="pubmed">35914832</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumusiime, C, Archer R, Muheki C, Kiggundu P, Ssemujju R, Nakyanzi A, et al. The cost of delivering COVID-19 vaccines in Kampala, Uganda. 2024. ThinkWell. Available from https://immunizationeconomics.org/wp-content/uploads/2024/05/thinkwell-report-uganda-final.pdf. Cited 2 Aug 2024.</Citation></Reference><Reference><Citation>Banks C, Estanislao RD, De los Reyes SJ, De Guzman JE, Sumpaico-Tanchanco LB, Makani-Lim B, Archer R, Boonstoppel L. The cost of delivering COVID-19 vaccines in the Philippines. 2023. ThinkWell. Available from: https://thinkwell.global/wp-content/uploads/2024/03/Cost-of-delivering-COVID19-vaccines-in-the-Philippines_final-report_19-Dec-2023.pdf. Cited 24 Jan 2024.</Citation></Reference><Reference><Citation>Nguyen VM, Moi F, Boonstoppel L, Duong HT, Vien CC, Van Hoang M. The cost of delivering COVID-19 vaccines in Vietnam. BMC Health Serv Res. 2024;24:779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11232236</ArticleId><ArticleId IdType="pubmed">38977967</ArticleId></ArticleIdList></Reference><Reference><Citation>Central Bank of Nigeria. Exchange rates. 2024. Available from: https://www.cbn.gov.ng/rates/ExchRateByCurrency.asp. Cited 8 Jan 2024.</Citation></Reference><Reference><Citation>Basinga P, Gertler PJ, Binagwaho A, Soucat AL, Sturdy J, Vermeersch CM. Effect on maternal and child health services in Rwanda of payment to primary health-care providers for performance: an impact evaluation. Lancet. 2011;377:1421–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21515164</ArticleId></ArticleIdList></Reference><Reference><Citation>Milstein R, Shatrov K, Schmutz LM, Blankart CR. How to pay primary care physicians for SARS-CoV-2 vaccinations: an analysis of 43 EU and OECD Countries. Health Policy. 2022;126:485–92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934248</ArticleId><ArticleId IdType="pubmed">35367056</ArticleId></ArticleIdList></Reference><Reference><Citation>Sowe A, Namatovu F, Cham B, Gustafsson PE. Does a pay-for-performance health service model improve overall and rural–urban inequity in vaccination rates? A difference-in-differences analysis from the Gambia. Vaccine X. 2022;12:100206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9424534</ArticleId><ArticleId IdType="pubmed">36051748</ArticleId></ArticleIdList></Reference><Reference><Citation>World Bank. Performance-based financing in the health sector of the Democratic Republic of Congo: Impact evaluation report. 2022. Available from: https://documents1.worldbank.org/curated/en/099747010062242661/pdf/IDU072eb74db09bad042910aff90ed0f1a8bee92.pdf. Cited 9 Feb 2024.</Citation></Reference><Reference><Citation>Frey B. Policy consequences of pay-for-performance and crowding-out. J Behav Econ Pol. 2017;1:55–9.</Citation></Reference><Reference><Citation>Sibeudu FT, Onwujekwe OE, Okoronkwo IL. Cost analysis of supplemental immunization activities to deliver measles immunization to children in Anambra state, south-east Nigeria. Vaccine. 2020;38:5947–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651114</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunization Economics Community of Practice. Immunization Delivery Cost Catalogue. 2024. Available from: https://immunizationeconomics.org/thinkwell-idcc/. Cited 2 Aug 2024.</Citation></Reference><Reference><Citation>Immunization Costing Action Network (ICAN). The cost of delivering yellow fever and meningitis A vaccines through campaigns in Nigeria. 2022. ThinkWell &amp; Nsukka: University of Nigeria. Available from: https://www.thinkwell.global/wp-content/uploads/2022/02/Nigeria-YF-campaign-costing-full-report.pdf. Cited 2 Aug 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>